Brazilian clinical trials have unveiled that a COVID-19 vaccine developed by China's Sinovac has been found to be 50.4% effective, media reports said.
It shows the vaccine is significantly less effective than previous data suggested - barely over the 50% needed for regulatory approval, reports BBC.
The vaccine is one of the two which the Brazilian government has lined up.
Brazil is one of the worst-hit COVID-19 nations in the world.
Sinovac, a Beijing-based biopharmaceutical company, is behind CoronaVac, an inactivated vaccine. It works by using killed viral particles to expose the body's immune system to the virus without risking a serious disease response, reports BBC.
- Smokers who switch to e-cigarettes may adopt other healthy routines: Study
- Total Covid-19 incidence rate in North Korea spikes to 1.2 mln
- WHO ready to support DPR Korea battle COVID-19 infections
- North Korea registers six deaths due to COVID-19
- China: Shanghai reports 322 confirmed, 3,625 asymptomatic local Covid-19 cases